Relmada Therapeutics, Inc. (RLMD)
NASDAQ: RLMD · Real-Time Price · USD
2.940
-0.350 (-10.70%)
Dec 3, 2024, 2:14 PM EST - Market open
Relmada Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
| Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
| Selling, General & Admin | 41.72 | 48.89 | 47.93 | 35.08 | 24.87 | 7.25 | |
| Research & Development | 49.93 | 54.81 | 113.32 | 90.62 | 34.47 | 7.86 | |
| Operating Expenses | 91.64 | 103.7 | 161.25 | 125.7 | 59.34 | 15.11 | |
| Operating Income | -91.64 | -103.7 | -161.25 | -125.7 | -59.34 | -15.11 | |
| Interest & Investment Income | 4.13 | 5.15 | 2.66 | 1.2 | 1.4 | 0.1 | |
| EBT Excluding Unusual Items | -87.51 | -98.55 | -158.59 | -124.5 | -57.94 | -15.01 | |
| Gain (Loss) on Sale of Investments | 1.02 | -0.24 | -4.81 | -1.25 | -0.02 | - | |
| Other Unusual Items | - | - | 6.35 | - | -1.5 | - | |
| Pretax Income | -86.49 | -98.79 | -157.04 | -125.75 | -59.46 | -15.01 | |
| Net Income | -86.49 | -98.79 | -157.04 | -125.75 | -59.46 | -15.01 | |
| Net Income to Common | -86.49 | -98.79 | -157.04 | -125.75 | -59.46 | -15.01 | |
| Shares Outstanding (Basic) | 30 | 30 | 30 | 18 | 16 | 9 | |
| Shares Outstanding (Diluted) | 30 | 30 | 30 | 18 | 16 | 9 | |
| Shares Change (YoY) | 0.15% | 1.59% | 68.80% | 12.56% | 68.97% | 46.22% | |
| EPS (Basic) | -2.87 | -3.28 | -5.30 | -7.16 | -3.81 | -1.63 | |
| EPS (Diluted) | -2.87 | -3.28 | -5.30 | -7.16 | -3.81 | -1.63 | |
| Free Cash Flow | -53.21 | -51.66 | -103.8 | -91.87 | -27.81 | -12.09 | |
| Free Cash Flow Per Share | -1.76 | -1.72 | -3.50 | -5.23 | -1.78 | -1.31 | |
| EBITDA | - | - | -161.25 | -125.7 | -59.33 | -15.1 | |
| D&A For EBITDA | - | - | 0 | 0 | 0 | 0 | |
| EBIT | -91.64 | -103.7 | -161.25 | -125.7 | -59.34 | -15.11 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.